High cumulative doxorubicin dose for advanced soft tissue sarcoma

Cancer shared this article with you from Inoreader High cumulative doxorubicin dose for advanced soft tissue sarcoma Via Latest Results for BMC Cancer Abstract Background The recommended cumulative doxorubicin dose in soft tissue sarcoma (STS) treatment was based on cardiotoxicity data from retrospective studies of breast cancer patients. However, the treatment and prognosis of STS and breast cancer are quite different, and reference to breast cancer data alone may not reflect the efficacy of doxorubicin treatment in STS. This study, thus, aimed to review and analyze clinical data of STS patients treated with a high cumulative doxorubicin dose, to provide a reference for treatment selection and clinical trial design. Methods We retrospectively collected and analyzed clinical data of patients with advanced STS who received doxorubicin-based chemotherapy from January 2016 to January 2020. The patients were divided into a standard-dose group (who received ≤6 cycles of doxorubicin after the initial diagnosis) and an over-dose group (who were re-administered doxorubicin [doxorubicin-rechallenge] after receiving 6 cycles of doxorubicin therapy discontinuously). Patient characteristics, cumulative doxorubicin dose, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), cardiotoxicity incidence, and treatment effectiveness were evaluated in both groups. Results A total of 170 patients with advanced STS were recruited (146 in the standard-dose group and 24 in the over-dose group). The average cumulative doxorubicin dose was 364.04 ± 63.81 mg/m2 in the standard-dose group and 714.38 ± 210.09 mg/m2 in the over-dose group. The ORR, DCR, and median PFS were 15.07, 58.9%, and 6 (95% confidence interval [CI]: 5.8–6.5) months in the standard-dose group and 16.67, 66.67%, and 4 (95%CI: 2.0–5.8) months in the over-dose group, respectively. Symptomatic heart failure occurred in five patients (3.42%) of the standard-dose group and in one patient (4.17%) of the over-dose group. In these patients with cardiotoxicity, doxorubicin was discontinued, and all of them died of uncontrolled tumor growth. No drug-related deaths occurred. Conclusions The continuation of or rechallenge with doxorubicin beyond the recommended cumulative dose could be a promising therapeutic option in the treatment of chemotherapy-sensitive advanced sarcomas. Further evaluation is necessary in prospective trials. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Bladder cancer stage and mortality: urban vs. rural residency

Cancer shared this article with you from Inoreader Bladder cancer stage and mortality: urban vs. rural residency Via Latest Results for Cancer Causes Abstract Objective Relative to urban populations, rural patients may have more limited access to care, which may undermine timely bladder cancer (BCa) diagnosis and even survival. Methods We tested the effect of residency status (rural areas [RA < 2500 inhabitants] vs. urban clusters [UC ≥ 2500 inhabitants] vs. urbanized areas [UA, ≥50,000 inhabitants]) on BCa stage at presentation, as well as on cancer-specific mortality (CSM) and other cause mortality (OCM), according to the US Census Bureau definition. Multivariate competing risks regression (CRR) models were fitted after matching of RA or UC with UA in stage-stratified analyses. Results Of 222,330 patients, 3496 (1.6%) resided in RA, 25,462 (11.5%) in UC and 193,372 (87%) in UA. Age, tumor stage, radical cystectomy rates or chemotherapy use were comparable between RA, UC and UA (all p > 0.05). At 10 years, RA was associated with highest OCM followed by UC and UA (30.9% vs. 27.7% vs. 25.6%, p < 0.01). Similarly, CSM was also marginally higher in RA or UC vs. UA (20.0% vs. 20.1% vs. 18.8%, p = 0.01). In stage-stratified, fully matched CRR analyses, increased OCM and CSM only applied to stage T1 BCa patients. Conclusion We did not observe meaningful differences in access to treatment or stage distribution, according to residency status. However, RA and to a lesser extent UC residency status, were associated with higher OCM and marginally higher CSM in T1N0M0 patients. This observation should be further validated or refuted in additional epidemiological investigations. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis

Cancer shared this article with you from Inoreader Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis Via Anti-Cancer Drugs - Published Ahead-of-Print Non-small cell lung cancer (NSCLC) is a major type of lung cancer, leading to a high fatality rate. The role of circular RNAs (circRNAs) in cancer has been increasingly emphasized and studied. However, the function of circ-ZNF124 in NSCLC is largely unclear, and associated regulatory mechanism is not studied. Here, we examined the expression pattern of circ-ZNF124 using quantitative real-time PCR. For functional analysis, cell proliferation, cell apoptosis/cycle and cell invasion were investigated using MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay, flow cytometry assay and transwell assay, respectively. As results, we found that the expression of circ-ZNF124 was elevated in NSCLC tissues and cells. Functionally, circ-ZNF124 downregulation inhibited NSCLC cell proliferation and invasion but induced apoptosis and cycle arrest in vitro, and blocked tumor growth in vivo by animal experiments. Mechanistically, we identified that miR-498 was a target of circ-ZNF124, and miR-498 directly bound to YES proto-oncogene 1 (YES1). Besides, rescue experiments discovered that the cellular effects caused by circ-ZNF124 downregulation could be reversed by miR-498 inhibition or YES1 overexpression. Moreover, we discovered that circ-ZNF124 downregulation inactivated the expression of β-catenin and c-Myc by mediating the miR-498/YES axis. In conclusion, these findings supported that circ-ZNF124 regulated the expression of YES1 by acting as a sponge of miR-498, thus restraining NSCLC development by inactivating the Wnt/β-catenin signaling pathway, which provided a novel strategy to treat NSCLC. Received 19 January 2020 Revised form accepted 3 October 2020 Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.anti-cancerdrugs.com. Correspondence to Fei Gao, Department of Oncology, The Third Hospital of Mianyang (Sichuan Mental Health Center), No. 190, East Section of Jiannan Road, Sichuan 621000, China, Tel: +86 08162271905; e-mail: ipp7ssf@163.com Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Weekly versus triweekly cisplatin-alone adjuvant chemoradiotherapy after radical hysterectomy for stages IB–IIA cervical cancer with risk of recurrence

Cancer shared this article with you from Inoreader Weekly versus triweekly cisplatin-alone adjuvant chemoradiotherapy after radical hysterectomy for stages IB–IIA cervical cancer with risk of recurrence Via Anti-Cancer Drugs - Published Ahead-of-Print Weekly and triweekly cisplatin-alone concomitant chemoradiotherapy regimens after radical surgery were compared in stages IB–IIA cervical cancer with intermediate- or high-risk factors to identify the better therapeutic regimen. We retrospectively analyzed patients with stages IB–IIA cervical cancer who received radical hysterectomy followed by concurrent adjuvant chemoradiotherapy to compare the efficiency between weekly and triweekly regimen groups. We evaluated between-group differences in survival, recurrence, compliance, and adverse effects. A total of 217 patients were included in this study (triweekly group vs. weekly group; 97 vs. 120). The mean follow-up was 47.2 months. The 5-year disease-free survival (DFS) was 84.4% or 76.5% for patients treated with triweekly c isplatin chemotherapy or the weekly regimen, respectively (P = 0.110). The 5-year overall survival (OS) was 82.4 and 78.6% for the same treatment groups, respectively (P = 0.540). The DFS of the patients with pelvic lymph node metastasis were marginally better in triweekly regimen group compared with the weekly group (P = 0.031). Grades 3–4 leukopenia was significantly more common in the triweekly group (P = 0.028). The weekly cisplatin chemotherapy group experienced the same therapeutic effect as the triweekly cisplatin-alone chemotherapy group but with less toxicity. However, triweekly cisplatin regimen reduced the recurrence in patients with pelvic lymph node metastasis. * Jiahao Zhu, Rui Lou, and Shengjun Ji contributed equally to the writing of this article. Received 15 May 2020 Revised form accepted 14 October 2020 Correspondence to Ke Gu, MD, PhD, Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, 200 Huihe Road, Wuxi, China, 214062, Tel: +86051088682999; fax: +051085808820; e-mail: drguke@163.com Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

EEG Characteristics during Short-Term Spontaneous Waking Periods of Different Durations with Changes in Psychomotor Activity Induced by Falling Asleep

xlomafota.13 shared this article with you from Inoreader EEG Characteristics during Short-Term Spontaneous Waking Periods of Different Durations with Changes in Psychomotor Activity Induced by Falling Asleep Via Latest Results for Neuroscience and Behavioral Physiology Changes in EEG spectral characteristics during periods of recovery of performance in a psychomotor test during spontaneous short-term periods of waking in daytime sleep were studied in 17 healthy subjects. The test consisted of two sequentially alternating tasks: to count from 1 to 10 silently accompanied by synchronized pressing of a button, and silent counting only. The monotonous nature of the test led to a rapid decline in the level of consciousness and, in most cases, induced falling asleep. Presses serves as a behavioral indicator of the recovery of cognitive processes inhibited during sleep. Situations with small (2–5) and relatively large (6–10) numbers of button presses were compared. The start of pressing was preceded by the appearance of generalized α rhythm, which decreas ed during performance of psychomotor activity. The power of this rhythm was always greater in longer periods of observed behavioral activity. The end of pressing returned α-power indicators to levels seen before waking. The EEG α rhythm in decreased consciousness during short-term waking evidently characterized the action of the thalamocortical activatory mechanism and was a necessary condition for motor interaction of the body with the external environment. The absence of any differences in the frontal areas at the initial stage on performance of short-lived activity and longer-lasting activity, approaching performance of the complete cycle of presses, suggested that they are involved to the same extent during this period regardless of the number of presses. This result may provide indirect support for the notion that the observed psychomotor activity, even with a small number of presses, is not automatic and unconscious but is accompanied by reduced and fragmented consciousness. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Cross-Correlation and Coherence Analysis of Electrocortigrams in Rats Subjected to Craniocerebral Trauma

xlomafota.13 shared this article with you from Inoreader Cross-Correlation and Coherence Analysis of Electrocortigrams in Rats Subjected to Craniocerebral Trauma Via Latest Results for Neuroscience and Behavioral Physiology Craniocerebral trauma (CCT) is one of the leading causes of death and long-term loss of work capacity among the young population of both the Russian Federation and other countries. The development of adequate and reproducible models of CCT in laboratory animals and objective methods for assessing the extent of neurological impairments gives cause for optimism in seeking and studying new and effective neurorehabilitation approaches. The aim of the present work was to carry out a comparative cross-correlation and coherence analysis of electrocorticograms from presumptively healthy rats and animals subjected to CCT. After initial trepanning, open penetrating CCT was modeled by controlled cortical impacts applied to the motor cortex of the left hemisphere. Nichrome corticographic recording el ectrodes were implanted bilaterally in the primary and secondary motor cortex and in the primary somatosensory cortex (above the hippocampus). Electrocorticograms were recorded on days 3 and 7 after surgery in the home cage and in the resting state. Cross-correlation analysis consisted of computing the cross-correlation coefficient, the mean frequency, and the maximum span in the cross-correlation function. Mean coherence power levels for the δ, θ, α, and β rhythms were computed for pairs of leads. Unilateral traumatic damage to the motor cortex and underlying structures led to impairment to the operation of interhemisphere and intrahemisphere connections and these changes were seen not only in the impact area, but also in distant parts of the cortex on post-trauma days 3 and 7. These changes in ECoG cross-correlation and coherence parameters occurring in rats as a result of CCT were similar to those seen in patients in clinical practice, so it can be suggested that this experim ental model can be used for neurophysiological and pharmacological research. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Absorbed dose simulation of meta - 211 At-astato-benzylguanidine using pharmacokinetics of 131 I-MIBG and a novel dose conversion method, RAP

xlomafota.13 shared this article with you from Inoreader Absorbed dose simulation of meta - 211 At-astato-benzylguanidine using pharmacokinetics of 131 I-MIBG and a novel dose conversion method, RAP Via Latest Results for Annals of Nuclear Medicine Abstract Objective We aimed to estimate in vivo 211At-labeled meta-benzylguanidine (211At-MABG) absorbed doses by the two dose conversion methods, using 131I-MIBG biodistribution data from a previously reported neuroblastoma xenograft model. In addition, we examined the effects of different cell lines and time limitations using data from two other works. Methods We used the framework of the Monte Carlo method to create 3200 virtual experimental data sets of activity concentrations (kBq/g) to get the statistical information. Time activity concentration curves were produced using the fitting method of a genetic algorithm. The basic method was that absorbed doses of 211At-MABG were calculated based on the medical internal radiation dose formalism with the conversion of the physical half-life time of 131I to that of 211At. We have further improved the basic method; that is, a novel dose conversion method, RAP (Ratio of Pharmacokinetics), using percent injected dose/g. Results Virtual experiments showed that 211At-MABG and 131I-MIBG had similar properties of initial activity concentrations and biological components, but the basic method did not simulate the 211At-MABG dose. Simulated 211At-MABG doses from 131I-MIBG using the RAP method were in agreement with those from 211At-MABG, so that their boxes overlapped in the box plots. The RAP method showed applicability to the different cell lines, but it was difficult to predict long-term doses from short-term experimental data. Conclusions The present RAP dose conversion method could estimate 211At-MABG absorbed doses from the pharmacokinetics of 131I-MIBG with some limitations. The RAP method would be applicable to a large number of subjects for targeted nuclide therapy. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.